Heritage Bio Labs · Research use only
Heritage Bio Labs
Front bottle artwork: Heritage Bio Labs SEMA / IGF-1 LR3 — 10 mg / 1 mg

Payment Options

  • Cash App logoCash App
  • Apple Pay logoApple Pay
  • PayPal logoPayPal
  • Crypto (USDC) logoCrypto (USDC)

$10 USPS Priority Shipping

Estimated delivery: 2–5 business days. Delivery times may vary.

Orders of $500 or more ship free. Final shipping details at checkout.

← Back to shop
!For Research Use Only

SEMA / IGF-1 LR3 — 10 mg / 1 mg

$74.99

SEMA / IGF-1 LR3 denotes a proposed semaglutide–growth-factor combination. Semaglutide is studied for GLP-1-mediated metabolic effects, while LR3 IGF-1 supports growth signaling in laboratory systems; blend-specific claims require separate attribution. For research use only; not for human or veterinary use.

Research Use Only. Not for human consumption, diagnostic use, or clinical application. Priced items use order requests; unpriced catalog listings are inquiry-only.

Full description

Educational research context. The cited studies and supplier descriptions do not verify the identity, testing, or effects of this Heritage product.

SEMA is a common abbreviation for semaglutide, a GLP-1 receptor agonist. IGF-1 LR3 is a modified form of insulin-like growth factor 1 used as a growth-promoting laboratory reagent. These components address different signaling systems: the semaglutide literature concerns metabolic regulation and body weight, whereas LR3 documentation emphasizes receptor-mediated cell survival and proliferation. The combined label does not identify a naturally occurring hormone or an approved fixed-combination medicine.

The STEP 1 trial studied semaglutide with lifestyle intervention in adults with overweight or obesity and reported greater average weight reduction than placebo. That study did not include IGF-1 LR3. GroPep’s LR3 product information concerns cell-culture supplementation rather than preservation of human muscle during semaglutide-associated weight loss. A possible body-composition rationale can be inferred from the pairing, but no exact Umbrella blend page or blend-specific trial was established in this review. Accordingly, descriptions such as fat loss with muscle support would need to be presented as a proposed combination concept, not as an outcome demonstrated by either component source.

Sources

  1. STEP 1 — semaglutide obesity trialExternal reference (requires review)
  2. GroPep — Human LR3 IGF-I specificationsExternal reference (requires review)
  3. Umbrella Labs — peptide-blend catalogSupplier listing (not independent scientific evidence)

For research use only. Not for human or veterinary use; not medical advice.

Questions? Chat with a real human.